What it's for (Indications)
- Febuxostat is indicated for the chronic management of hyperuricemia in adult patients with gout.
- Its primary purpose is to lower serum uric acid (SUA) levels to reduce the frequency of gout flares and to facilitate the dissolution of urate crystals that contribute to the pathogenesis of gout.
- This medication is specifically prescribed for patients who have already experienced the clinical manifestations of gout, such as recurrent acute gouty arthritis or tophaceous gout.
- It is crucial to note that febuxostat is not indicated for the treatment of asymptomatic hyperuricemia, where elevated serum uric acid levels are present without any clinical signs or symptoms of gout.
- The decision to initiate febuxostat therapy should be based on a confirmed diagnosis of gout and the need for long-term urate-lowering therapy to achieve and maintain a target serum uric acid level, typically below 6 mg/dL, to prevent disease progression and improve patient outcomes.
- Its use should be carefully considered, especially in patients with underlying cardiovascular conditions, given important safety information.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The recommended starting dose of febuxostat is 40 mg once daily. For patients who do not achieve a serum uric acid (SUA) level less than 6 mg/dL after two weeks of treatment with 40 mg, the dose may be increased to 80 mg once daily. The maximum recommended dose of febuxostat is 80 mg once daily. It can be taken orally, with or without food. No dose adjustment is necessary for patients with mild to moderate renal impairment or mild to moderate hepatic impairment. However, caution is advised in patients with severe renal impairment (creatinine clearance less than 30 mL/min) or severe hepatic impairment, as clinical experience is limited in these populations. It is important to monitor serum uric acid levels periodically to ensure the therapeutic target is met and to adjust the dose as appropriate. During the initial period of treatment, patients may experience an increase in gout flares due to the mobilization of urate stores; therefore, concomitant prophylactic therapy with colchicine or a non-steroidal anti-inflammatory drug (NSAID) is often recommended for up to six months. |
Safety & Warnings
Common Side Effects
- Commonly reported side effects associated with febuxostat treatment include liver function abnormalities (elevations in serum transaminase levels), nausea, arthralgia, rash, and the precipitation of acute gout flares, particularly during the initial phase of therapy.
- While these initial gout flares can be distressing, they are often indicative of the drug's effectiveness in mobilizing urate stores and can be managed with prophylactic co-medication.
- More serious, albeit less common, side effects warrant careful consideration.
- These include cardiovascular thrombotic events (e.
- g.
- , myocardial infarction, stroke), which have been highlighted by post-marketing studies and clinical trials, particularly in patients with pre-existing cardiovascular disease.
- Additionally, hypersensitivity reactions, ranging from mild skin rashes to severe cutaneous adverse reactions such as Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and drug reaction with eosinophilia and systemic symptoms (DRESS), have been reported.
- Patients should be advised to seek immediate medical attention if they experience symptoms indicative of a severe allergic reaction or cardiovascular event.
- Regular monitoring of liver function tests is also recommended.
Serious Warnings
- Black Box Warning: WARNING: CARDIOVASCULAR DEATH. Gout patients with established cardiovascular (CV) disease treated with febuxostat tablets had a higher rate of CV death compared to those treated with allopurinol in a CV outcomes study. Consider the risks and benefits of febuxostat tablets when deciding to prescribe or continue patients on febuxostat tablets. Febuxostat tablets should only be used in patients who have an inadequate response to a maximally titrated dose of allopurinol.
- Febuxostat carries significant warnings, particularly concerning cardiovascular safety.
- A major clinical trial (CARES study) in patients with gout and established cardiovascular disease indicated an increased risk of cardiovascular death with febuxostat compared to allopurinol.
- Therefore, febuxostat should generally be reserved for patients who have an inadequate response to a maximally tolerated dose of allopurinol, or who are intolerant to allopurinol, especially those with pre-existing cardiovascular disease.
- Patients should be thoroughly evaluated for cardiovascular risk factors prior to and during treatment.
- During the initiation of febuxostat therapy, an acute gout flare may occur due to the rapid reduction in serum uric acid levels, leading to the mobilization of urate from tissue deposits.
- Prophylactic treatment with colchicine or an NSAID for up to six months is highly recommended to mitigate this risk.
- Liver enzyme elevations are common, and periodic monitoring of liver function tests is advised.
- Rare but severe hypersensitivity reactions, including SJS, TEN, and DRESS, have been reported; patients should be instructed to discontinue febuxostat immediately and seek medical attention if such reactions occur.
- Febuxostat is not indicated for the treatment of asymptomatic hyperuricemia.
- Concomitant use with azathioprine or mercaptopurine is contraindicated due to the risk of significant toxicity from increased concentrations of these drugs.
How it Works (Mechanism of Action)
Febuxostat is a potent, non-purine selective inhibitor of xanthine oxidase (XOI). Xanthine oxidase is an enzyme crucial in the purine catabolism pathway, responsible for the sequential oxidation of hypoxanthine to xanthine, and then to uric acid, which is the end product of purine metabolism in humans. By selectively binding to and inhibiting both the oxidized and reduced forms of xanthine oxidase, febuxostat effectively blocks the conversion of purine precursors into uric acid. This inhibition leads to a significant reduction in the systemic production of uric acid, consequently lowering serum uric acid (SUA) concentrations. The decrease in SUA levels below the saturation point for urate (typically 6.8 mg/dL) promotes the dissolution of existing urate crystals that have accumulated in joints and other tissues, and prevents the formation of new crystals. This action is fundamental to the long-term management of gout, alleviating symptoms and preventing disease progression. Unlike some other XOIs, febuxostat's non-purine structure provides a distinct advantage in terms of reduced potential for drug interactions with other purine analogues. Its potent and sustained inhibition of xanthine oxidase contributes to its efficacy in achieving and maintaining target SUA levels.